Pınar GÖKÇEN, Erol ÇAKMAK, Gupse ADALI, Halef DOGAN, Hatice ÖZER, Oguzhan OZTURK, Hamdi Levent DOĞANAY, Kamil OZDİL

Predictive Value of the Intestinal Free Fatty Acid Binding Protein in Celiac Disease

Amaç: Şizofreni tanılı hastalarda klozapin ile eşzamanlı olarak uygulanan elektrokonvulziv tedavinin daha iyi tedavi yanıtı ve hastanede yatış süresinde kısalmaya neden olma olasılığını incelemek amaçlanmıştır. Yöntemler: Kadın psikiyatri servisimizde 5 yıl boyunca (01.02.2014 ve 01.02.2019 arasında) yatarak tedavi gören şizofreni tanılı hastaların tıbbi kayıtları retrospektif olarak incelendi. Tedavi yanıtını değerlendirmede Klinik Global İzlem – İyileşme (KGİ-İ) ölçeği kullanılmıştı. Bulgular: EKT ile tedavi edilmiş olan 191 olgu içinde; 8 şizofreni olgusu (K-EKT) EKT ve eşzamanlı klozapin ile tedavi edilmiş ve 14 olguya ise (EKT-Ö) önce EKT uygulanmış, sonrasında klozapin tedavisine başlanmıştı. İki grup arasında EKT seans sayıları ve nöbet süreleri açısından anlamlı fark yoktu (p > 0,05). EKT’ ye yanıt oranının (KGİ-İ: 2 ya da 3), K-EKT grubunda %75 (n=6); EKT-Ö grubunda ise %85,7 (n=12) olduğu görüldü. Ortalama KGİ-İ skorları arasında gruplar arasında anlamlı fark yoktu (p > 0,05). K-EKT grubunun hastanede yatış süresi (37,7  14,44 gün), EKT-Ö grubundan (56,0  19,2 gün) daha kısaydı (p = 0,04). EKT seansları sırasında ya da yatışlar süresince ciddi yan etki görülmedi. Sonuç: Her iki uygulamada da tedaviye iyi yanıt yüksek orandaydı ve anlamlı fark yoktu. EKT ile eşzamanlı klozapin uygulamasının hastanede yatış süresini anlamlı oranda kısaltırken ciddi bir komplikasyona ve yan etki artışına neden olmadığı görüldü.

Anahtar Kelimeler:

EKT, Şizofreni, Klozapin

Predictive Value of the Intestinal Free Fatty Acid Binding Protein in Celiac Disease

Purpose: Determining whether adjunctive electroconvulsive therapy (ECT) with clozapine leads to better treatment response and fewer days in hospital for patients with schizophrenia. Methods: Medical records of patients with schizophrenia who were treated with ECT-clozapine combination in our women’s mental health clinic in a period of 5 years (between 01.02.2014 and 01.02.2019) were investigated retrospectively. Clinical Global Impression of Improvement (CGI-I) scale was used for assessing treatment response. Results: Of the 191 cases treated with ECT, there were 8 cases of schizophrenia who were treated with ECT and concomitant clozapine (C-ECT) and 14 cases who were treated with ECT before the initiation of clozapine (ECT-B). Number of ECT sessions and duration of seizures were not significantly different for both groups (p > 0.05). There was good and mild response (CGI-I score of 2 and 3) in 75% of the patients (n=6) for C-ECT and 85.7% of the patients (n=12) for ECT-B. Mean CGI-I scores between the two groups were not significantly different (p > 0.05). Duration of hospitalization for the C-ECT group (37.7  14.44 days) was shorter than the duration of hospitalization for the ECT-B group (56.0  19.2 days) (p = 0.04). No serious adverse events were observed during the ECT sessions or during the index hospitalizations Conclusion: Response rate was high and similar with both of the procedures and the duration of hospitalization was shorter for C-ECT group with no major complication and no significant increase in adverse effects.

Keywords:

ECT, Schizophrenia, Clozapine,

___

1. Vreugdenhil AC, Wolters VM, Adriaanse MP, et al. Additional value of serum I-FABP levels for evaluating celiac disease activity inchildren. Scand J Gastroenterol. 2011;46:1435-41. DOI:10.3109/00365521.201 1.627447
2. Adriaanse MP, Tack GJ, Passos VL, et al. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Aliment Pharmacol Ther. 2013;37:482-90. DOI:10.1111/apt.12194.
3. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol. 1999;11:1185-94. DOI: 10.1097/00042737-199910000-00019
4. Rubio TA, Hill ID, Kelly CP, et al. ACG clinical guidelines: Diagnosis and management of celiac disease. Am J Gastroenterol. 2013;108:656- 76. DOI: 10.1038/ajg.2013.79
5. Volta U, Fabbri A, Parisi C, et al. Old and new serological test for celiac disease screening. Expert Rev Gastroenterol Hepatol. 2010;4:31-5. DOI: 10.1586/egh.09.66
6. Lewis NR, Scott BB. Meta-analysis: deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease. Aliment Pharmacol Ther. 2010;31:73-81. DOI: 10.1111/j.1365-2036.2009.04110.x.
7. Adriaanse MPM, Mubarak A, Riedl RG, et al. Progress towards noninvasive diagnosis and follow-up of celiac disease in children; a prospective multicentre study to the usefulness of plasma I-FABP. Sci Rep. 2017;7:8671. DOI: 10.1038/s41598-017-07242-4.
8. Ho SSC, Keenan JI, Day AS. The Role of Gastrointestinal-Related Fatty Acid-Binding Proteins as Biomarkers in Gastrointestinal Diseases. Dig Dis Sci. 2020;65:376-90. DOI: 10.1007/s10620-019-05841-x
9. Not T, Ziberna F, Vatta S, et al. Cryptic genetic gluten intolerance revealed by intestinal antitransglutaminase antibodies and response to gluten-free diet. Gut. 2011;6011:1487-93. DOI: 10.1136/ gut.2010.232900
10. Salardi S, Volta U, Zucchini S, et al. Prevalence of celiac disease in children with type 1 diabetes mellitus increased in the mid-1990s: an 18-year longitudinal study based on anti-endomysial antibodies. J Pediatr Gastroenterol Nutr. 2008;46:612-4. DOI: 10.1097/ MPG.0b013e31815d697e.
11. Shamaly H, Hartman C, Pollack S, et al. Tissue transglutaminase antibodies are a useful serological marker for the diagnosis of celiac disease in patients with Down syndrome. J Pediatr Gastroenterol Nutr. 2007;44:583-6. DOI: 10.1097/MPG.0b013e3180320679.
12. Sardy M, Csikos M, Geisen C, et al. Tissue transglutaminase ELISA positivity in autoimmune disease independent of glutensensitive disease. Clin Chim Acta. 2007;376:126-35. DOI: 10.1016/j. cca.2006.08.006
13. Sood A, Khurana MS, Mahajan R, et al. Prevalence and clinical significance of IgA anti-tissue transglutaminase antibodies in patients with chronic liver disease. J Gastroenterol Hepatol. 2017;32:446-50. DOI: 10.1111/jgh.13474
14. Oldenburger IB, Wolters VM, Kardol-Hoefnagel T, et al. Serum intestinal fatty acid-binding protein in the noninvasive diagnosis of celiac disease. APMIS. 2018;126:186-90. DOI: 10.1111/apm.12800
15. Dipper CR, Maitra S, Thomas R, et al. Anti-tissue transglutaminase antibodies in the follow-up of adult coeliac disease. Aliment Parmacol Ther. 2009;30:236-244. DOI: 10.1111/j.1365-2036.2009.04039.x
16. Gidrewicz D, Trevenen CL, Lyon M, et al. Normalization time of celiac serology in children on a gluten-free diet. J Pediatr Gastroenterol Nutr. 2017;64:362-7. DOI: 10.1097/MPG.0000000000001270
17. Al-Toma A, Volta U, Auricchio R, et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterol J. 2019;7:583-613. DOI: 10.1177/2050640619844125